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Oxygen-dependent HIF1a hydroxylation and degra-
dation are strictly controlled by PHD2. In hypoxia,
HIF1a partly escapes degradation because of low
oxygen availability. Here, we show that PHD2 is
phosphorylated on serine 125 (S125) by the mecha-
nistic target of rapamycin (mTOR) downstream
kinase P70S6K and that this phosphorylation in-
creases its ability to degrade HIF1a. mTOR blockade
in hypoxia by REDD1 restrains P70S6K and un-
leashes PP2A phosphatase activity. Through its reg-
ulatory subunit B55a, PP2A directly dephosphory-
lates PHD2 on S125, resulting in a further reduction
of PHD2 activity that ultimately boosts HIF1a accu-
mulation. These events promote autophagy-medi-
ated cell survival in colorectal cancer (CRC) cells.
B55a knockdown blocks neoplastic growth of CRC
cells in vitro and in vivo in a PHD2-dependent
manner. In patients, CRC tissue expresses higher
levels of REDD1, B55a, and HIF1a but has lower
phospho-S125 PHD2 compared with a healthy colon.
Our data disclose a mechanism of PHD2 regulation
that involves the mTOR and PP2A pathways and
controls tumor growth.
INTRODUCTION
Tumor hypoxia correlates with unfavorable disease outcome,
malignancy, and resistance to therapy (De Bock et al., 2011).
The main executors of the cellular response to hypoxia are theCell Rep
This is an open access article under the CC BY-Nhypoxia-inducible factors (HIFs) HIF1 and HIF2, which are
negatively regulated by the HIF prolyl hydroxylase (PHD) family
members PHD1, PHD2, and PHD3. Following hydroxylation
in specific prolyl residues, the alpha subunits of HIF1 and HIF2
are targeted for ubiquitination and proteasomal degradation
(Epstein et al., 2001; Keith et al., 2011).
Although the activity of PHDs is reduced by hypoxia, this is a
graded effect, and, because of their high affinity for oxygen
(KM = 100–250 mM), significant PHD activity is still observed
at 1% oxygen (Chan et al., 2005; Epstein et al., 2001; Pan
et al., 2007; Stolze et al., 2004). Indeed, several reports docu-
ment that HIFs still become hydroxylated under nearly anoxic
conditions (Chan et al., 2005; Epstein et al., 2001). Under these
conditions, manipulation of PHD levels or activity can be a key
determinant in the hydroxylation rate of HIFa (Chan et al.,
2005; Epstein et al., 2001; Pan et al., 2007; Stolze et al., 2004).
Transcriptional induction of PHD2 and PHD3 (EGLN1 and
EGLN3, respectively) during chronic hypoxia presumably pre-
vents a deleterious HIF response upon reoxygenation (Appelhoff
et al., 2004; Epstein et al., 2001; Ginouve`s et al., 2008).
Although HIF levels have mostly been associated with a poor
prognosis of several tumor histotypes, the correlation between
PHD abundance and cancer progression is less clear (Jokilehto
and Jaakkola, 2010). This is likely due to the fact that mecha-
nisms besides protein level regulation, including oxygen,
cofactor bioavailability, and post-translational modifications
(e.g., SUMOylation), can regulate the enzymatic function of
PHDs (Jokilehto and Jaakkola, 2010; Nu´n˜ez-O’Mara et al.,
2015; Ortmann et al., 2016). The presence of phosphorylation
sites in PHD2 has been predicted (http://www.phosphonet.ca),
but their functional role is unclear.
mTOR is one of the main kinases involved in the regulation of
protein synthesis and cell growth in response to nutrients andorts 18, 1699–1712, February 14, 2017 ª 2017 The Author(s). 1699
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Phosphorylation of S125 by P70S6K Is Important to Control HIF1a Levels
(A) MS/MS spectrum of NH2-AKPPADPAAAAS
< p > PCR-COOH (S < p > indicates phosphoserine). Nine of 15 amino acids, including the phosphorylated serine,
are covered by a ladder of y-type fragment ions. The neutral loss peak (98 Da) characteristic for phosphorylated peptides is the most intense peak of the
spectrum at 492.9 mass-to-charge ratio (m/z).
(legend continued on next page)
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growth factors.When normal or cancer cells are exposed to star-
vation, mTOR is inhibited, and autophagy is induced mainly as
a survival response. mTOR is also involved in the hypoxia
response. In particular, HIF1a stabilization leads to early tran-
scription of REDD1, which works as a negative regulator of
mTOR and restrains its activity in hypoxia (Brugarolas et al.,
2004). Full inactivation of mTOR also requires the engagement
of the PP2A phosphatase (Hartley and Cooper, 2002; Peterson
et al., 1999; Roberts et al., 2014), further blocking this pathway
by directly dephosphorylating and inhibiting P70S6-kinase
(P70S6K) downstream of mTOR.
PP2A is a ubiquitously expressed serine-threonine phospha-
tase. It is a trimeric complex formed by a catalytic C subunit, a
scaffold A subunit, and a regulatory B subunit, which confers
specificity of PP2A for selective substrates. Fifteen B subunit
genes encoding 26 different isoforms give rise to more than
100 combinations of the PP2A holoenzyme, leading to a large
spectrum of biological activities (Seshacharyulu et al., 2013). In
cancer, PP2A is considered to be a tumor suppressor because
its main inhibitor, okadaic acid, was shown to have tumor-
promoting activity (Bialojan and Takai, 1988). However, the
complexity of the PP2A structure suggests that the presence
of different B subunits might determine different phenotypes in
the context of cancer.
RESULTS
P70S6K-Mediated Phosphorylation of PHD2 on S125
Controls HIF1a Levels
Mass spectrometry analysis of wild-type PHD2 (PHD2WT) re-
vealed three phosphorylation sites in S12, S14, and S125. Muta-
tion of S125 to alanine (PHD2S125A) impaired PHD2 ability to
reduce the signal emitted by a luciferase fused to an oxygen-
dependent degradation domain (Luc-ODDD) or to degrade
HIF1a compared with wild-type PHD2 (Figures 1A–1C; Table(B) Luciferase activity of HEK293T cells stably overexpressing an oxygen-depend
type (WT) or mutant PHD2 (S12A, S14A, and S125A) or an empty vector (EV) as
(C) Western blot (WB) of HEK293T cells transfected with HIF1a, alone (EV) or in
(D) WB of HEK293T cells transfected with HIF1a, alone (EV) or in combination w
(E) WB of DLD1 cells transfected with PHD2WT, PHD2S125A, and PHD2S125D and
(F) HT29 cells were transfected with an EV or with PHD2WT, PHD2S125A, and PHD
exposed to hypoxic conditions for 4 hr, and whole cell extracts (WCEs) were ana
(G) DLD1 cells were transfected with PHD2WT, PHD2S125A, and PHD2S125D. After
were analyzed by WB.
(H) HEK293T or DLD1 cells were transfected with HIF1a, alone (EV) or in combina
antibody against OH-HIF1a.
(I) WB of DLD1 cells transfected with PHD2WT, PHD2S125A, and PHD2S125D and t
(J) WB of HEK293T cells transfected with PHD2 treated with 1 mM Rapamycin, 2
(K) DLD1 cells were transfected with either EV or FLAG-PHD2 and with a control
24 hr, cells were lysed, and WCEs were analyzed by WB (left). 1 mg of EV or FLA
endogenous P70S6K kinase (right).
(L) Purified FLAG-PHD2 and PHD2 S125 proteins were phosphorylated with active
P70S6K inhibitor LY2584702 was used to a final concentration of 50 mM. Prote
detected by autoradiography (left). A WB of PHD2 input was used as a loading c
(M) HEK293T were transfected with FLAG-PHD2 and silenced with siP70S6K or
FLAG-PHD2 lysate was immunoprecipitated using anti-FLAG M2 beads to detec
(N) WB of DLD1 cells transfected with siCTR or siP70S6K and exposed to hypox
(O) WB of HEK293T cells overexpressing HIF1a and silenced with siP70S6K or s
All WBs were repeated three times on independent biological replicates. *p < 0.
mean ± SEM. See also Figure S1.S1), suggesting that phosphorylation at S125modulates its func-
tion. In contrast, PHD2S12A or PHD2S14A mutants displayed
similar activity as PHD2WT (Figures 1B and 1C). To further inves-
tigate the effect of PHD2 mutants on HIF1a levels, we trans-
fected HEK293T or DLD1 cells with PHD2WT, PHD2S125A,
or PHD2S125D (which mimics constitutive phosphorylation).
PHD2WT as well as PHD2S125D induced degradation of both
exogenous and endogenous HIF1a (Figures 1D and 1E; Table
S1), whereas the mutant PHD2S125A showed impaired function.
Similarly, HT29 cells exposed to the proteasome inhibitor
MG132 showed partial HIF1a degradation upon overexpression
of PHD2WT and PHD2S125D but not of PHD2S125A (Figure 1F;
Table S1). Prolonged exposure to MG132 overruled the differen-
tial activity of all PHD2 isoforms (PHD2WT, PHD2S125A, and
PHD2S125D), as indicated by the equalized HIF1a levels (Fig-
ure S1A). In hypoxia, the activity of these PHD2 isoforms on
HIF1a resembled what was observed previously (Figure 1F; Ta-
ble S1). Moreover, the half-life of HIF1a was strongly reduced in
the presence of PHD2WT and PHD2S125D, whereas, under the
same conditions, expression of PHD2S125A correlated with a
longer HIF1a half-life (Figure 1G). To test whether PHD2 phos-
phorylation might affect its enzymatic activity, we measured
HIF1a hydroxylation. In both HEK293T and DLD1 cells, hydrox-
ylation of overexpressed HIF1a was 40% to 55% lower in
the presence of PHD2S125A than with PHD2WT (Figure 1H). Simi-
larly, upon treatment with the proteasome inhibitor MG132
(which equalizes the total levels of HIF1a under all conditions),
hydroxylation of endogenous HIF1a by PHD2S125A was halved
compared with the amount detected in the presence of PHD2WT
(Figure 1I). These data indicate that the lack of phosphorylation
of PHD2 on S125 impairs its hydroxylase function, leading to a
longer HIF1a half-life.
To unveil the kinase responsible for PHD2 phosphorylation,
we blocked the predicted PHD serine kinases (http://www.
phosphonet.ca) and used a specific phospho-PHD2 antibodyent degradable luciferase (Luc-ODDD) transfected with plasmids carrying wild-
a control.
combination with WT or mutant PHD2 (S12A, S14A, and S125A).
ith PHD2WT, PHD2S125A, or PHD2S125D.
exposed to hypoxia for 4 hr.
2S125D. After 16 hr, cells were treated with the proteasome inhibitor MG132 or
lyzed by WB.
16 hr, cells were treated with cycloheximide for the indicated time, and WCEs
tion with PHD2WT or PHD2S125A. Hydroxylation of HIF1awas detected by using
reated with MG132 (10 mM) for 8 hr.
00 nM Torin2, 10 mM PD169316, and 10 mM PD19058 for 16 hr.
(siCTR) or a small interfering RNA (siRNA) targeting P70S6K (siP70S6K). After
G-PHD2 lysate was immunoprecipitated using anti-FLAG M2 beads to detect
P70S6K kinase in the presence of [32P]-g-ATP for 20min at 30C. The specific
ins were separated by 10% SDS-PAGE, and incorporated radioactivity was
ontrol (right).
siCTR. Then cells were lysed, and WCEs were analyzed by WB. 1 mg of EV or
t endogenous phosphorylated PHD2 (right).
ia for 4 hr.
iCTR.
05 versus EV in (B) and versus all other conditions in (H) and (I). Graphs show
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Figure 2. PP2A/B55a Specifically Binds and Dephosphorylates PHD2 in S125
(A) Schematic of the PP2A holoenzyme. Subunits A (scaffold subunit) and C (catalytic subunit) form a complex that can combine with different regulatory
B subunits responsible for the substrate and cell type specificity. B55a represents the a isoform of the family PR55.
(B) HEK293T cells were transfected with EV, B55a (FLAG-B55a), or PHD2 (FLAG-PHD2), andWCEswere analyzed byWB (right, WCE). 1 mg of EV or FLAG-B55a
lysate was immunoprecipitated using anti-FLAG M2 beads to detect endogenous PHD2. 1 mg of EV or FLAG-PHD2 lysates was immunoprecipitated with anti-
FLAG M2 beads to detect endogenous B55a.
(C) In vitro-translated pcDNA3/FLAG-PHD2 (FLAG-PHD2) or pcDNA3/FLAG (EV) was immunoprecipitated with anti-FLAGM2 beads after incubationwith in vitro-
translated B55a (HA-B55a), and immunocomplexes were detected by WB analysis.
(D and E) WCEs from DLD1 (D) or HT29 (E) were collected and immunoprecipitated with anti-B55a or anti-immunoglobulin G (IgG) as a control, and endogenous
PHD2 in immunocomplexes was detected by WB analysis.
(F) WB of DLD1 cells transfected with either HIF1a or an HIF1a proline mutant (HIF1a-PP) and with siCTR or B55a (siB55a).
(G) WB of HEK293T cells transfected with an EV or PHD2 (WT or S125A), alone and in combination with B55a. After 24 hr, WCEs were analyzed by WB.
(H) In vitro phosphatase assay in which two synthetized peptides from PHD2 (WT or mutant sequence) and a positive control peptide were used as substrate of
cell-isolated PP2A complex. The result indicates the absorbance released by free phosphate groups following the dephosphorylation reaction. NT, not treated.
(legend continued on next page)
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as readout. Torin2 and Rapamycin, both blocking the mTOR
pathway,were able to downmodulate phospho-PHD2 (Figure 1J;
Table S1). In fact, we found that the serine/threonine kinase
P70S6K, an mTOR target, was able to bind (Figure 1K) and
directly phosphorylate PHD2 in vitro and in vivo (Figures 1L
and 1M). Furthermore, P70S6K knockdown caused increased
levels of both hypoxia-induced and overexpressed HIF1a (Fig-
ures 1N and 1O). Altogether, these results show that P70S6K
phosphorylates PHD2 on S125, leading to enhanced HIF1a
degradation.
PP2A/B55a Specifically Binds and Dephosphorylates
PHD2 on S125
To assess whether a specific phosphatase complex could
interact with PHD2, we performed a stable isotope labeling
with amino acids in cell culture (SILAC)-based mass spectrom-
etry analysis from which it emerged that the B55a regulatory
subunit of the phosphatase family PP2Awas able to co-immuno-
precipitate with PHD2 (Table S2; Figure 2A). In HEK293T cells,
overexpressed B55a pulls down endogenous PHD2 (Figure 2B,
left). Vice versa, overexpressed PHD2 interacts with endoge-
nous B55a (Figure 2B, right). Because in vitro-translated PHD2
and B55awere able to bind each other in a cell-free system (Fig-
ure 2C), this binding is direct and does not require other partners.
In both DLD1 and HT29 colorectal cancer (CRC) cells, endoge-
nous PHD2 and B55a were able to bind to each other (Figures
2D and 2E; Figure S1B), suggesting that this interaction occurs
in different cell lines. PHD2 could pull down the PP2A catalytic
subunit Ca aswell, but only in the presence of B55a (Figure S1C).
This interaction was specific for B55a because PHD2 did not
bind in vitro-translated B55b, g, or d (Figure S1D). Thus, PHD2
interacts with PP2A specifically through B55a.
We then assessed the effect of this interaction on PHD2 activ-
ity with respect to HIF1a stabilization. Co-expression of B55a
prevented the degradation of HIF1a induced by PHD2WT but
failed to regulate the activity of PHD2S125A, indicating that
PP2A/B55a acts specifically on S125 (Figure S1E). Only PHD2,
but not PHD1 or PHD3, activity was increased by the administra-
tion of the PP2A inhibitor LB100, pointing to the specific rele-
vance of this post-translational modification for PHD2 but not
for the other family members (Figure S1F). Supporting the inhib-
itory effect of PP2A/B55a on PHD2-mediated HIF1a degrada-
tion, silencing of B55a in HEK293T cells could reduce the levels
of wild-type HIF1a, but it did not have any effect on the HIF1a
mutant (HIF1a-PP and also HIF1aP402A/P564G), where P402 and
P564 (normally hydroxylated by PHD2) were replaced by alanine
and glycine, respectively (Figure 2F; Table S3). Proving the direct
effect of PP2A/B55a on PHD2 phosphorylation, B55a overex-
pression could reduce the phosphorylation of PHD2WT on
S125, whereas phosphorylation of PHD2S125A was undetectable(I and J) In vitro dephosphorylation assay where FLAG-PHD2 isolated from
in dephosphorylation buffer (J). The anti-FLAG immunoprecipitation performe
munocomplexes (I). The phosphorylation status of PHD2 was detected by WB u
(K and L) DLD1 cells were transfected with siCTRL, or siB55a, or siP70S6K in trip
performed. Phosphorylated and non-phosphorylated PHD2 were absolutely quan
reference peptides of known concentrations (K). WB of the samples was perform
All WBs and immunoprecipitations were repeated three times on independent bunder these conditions (Figure 2G; Table S3). A phosphatase
assay showed that PP2A/B55a induced dephosphorylation of
a PHD2-derived peptide in S125 (or of a standard peptide
used as a positive control) but not of the mutated form (Fig-
ure 2H). This reaction was prevented by the PP2A inhibitor
okadaic acid (OA) (Figure 2H). To confirm this observation,
recombinant PHD2WT was dephosphorylated at S125 in the
presence of purified B55a-containing PP2A complex (Figures
2I and 2J; Table S3). Similarly, phosphorylation of endogenous
PHD2 was increased by silencing of B55a and decreased by
silencing of P70S6K (Figure 2K), whereas total PHD2 levels
were not affected (Figure 2L; Table S3). Altogether, these data
demonstrate that PHD2 is dephosphorylated on S125 by
PP2A/B55a and phosphorylated by the kinase P70S6K.
Release of PP2A/B55a Activity in Hypoxia Leads to
PHD2 Dephosphorylation and Enhanced HIF1a
Accumulation and Activity
To understand the relevance of PHD2 dephosphorylation in hyp-
oxia, we exposed HT29 and DLD1 cells to low oxygen tensions;
i.e., 1%, a concentration that still allows HIF hydroxylation by
PHD2 (Berra et al., 2003; Figures 3A and 3B; Table S4). Under
this condition, B55a knockdown prevented hypoxic HIF1a accu-
mulation and activity in a PHD2-dependent manner (Figures 3A–
3C; Table S4). Vice versa, degradation of HIF1a or Luc-ODDD in
hypoxia could be achieved by overexpressing PHD2, but this
process was prevented by co-expression of exogenous B55a
(Figures S2A and S2B). These data demonstrate that, in hypoxia,
PP2A/B55a contributes to HIF1a stabilization by dephosphory-
lating PHD2. Indeed, in a time-course fashion, we show that
the peak of HIF1a occurs earlier in the presence of B55a than
in its absence (Figure 3D) and that this event is associated with
dephosphorylation of endogenous PHD2 already after exposure
to hypoxia for 4 hr and, more robustly, at 16 hr (Figure 3E). Of in-
terest, this dephosphorylation correlates with a progressive in-
crease of PP2A activity, strongly reduced by siB55a or OA as
control (Figure 3F). These data indicate a hypoxic molecular
flow that, starting from the increase in PP2A/B55a activity, al-
lows the decrease in PHD2 phosphorylation and, thus, HIF1a
stabilization. Noteworthy is that, along the same time course, a
progressive decrease of phosphorylated P70S6K occurs, partly
antagonized by siB55a (Figure 3D). To further ascertain the tem-
poral link between mTOR and P70S6K and PP2A, HIF1a accu-
mulation was analyzed following reactivation of the mTOR
pathway by silencing the hypoxia-induced mTOR inhibitor
REDD1 (Brugarolas et al., 2004; Sofer et al., 2005). REDD1
silencing reduced HIF1a levels under hypoxic conditions, con-
firming that inhibition of mTOR signaling in hypoxia is favoring
HIF1a stabilization (Figure 3G). B55a silencing also reduced
HIF1a accumulation, and combination of both REDD1 andHEK293T cells was incubated alone or with immune-purified FLAG-B55a
d to isolate B55a shows the presence of PP2A/A and PP2A/C in the im-
sing a phospho-specific antibody (phospho-S125).
licate. Total proteins were extracted, and liquid chromatography (LC)/MS was
tified using parallel-reaction monitoring (PRM) and stable isotope-labeled (SIL)
ed as a control (L).
iological replicates. The graphs show mean ± SEM. See also Figure S2.
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Figure 3. Hypoxia Blocks mTOR and Releases PP2A/B55a Activity to Dephosphorylate PHD2 and Increase HIF1a Protein Levels and Activity
(A and B) HT29 (A) or DLD1 (B) cells were transiently transfected with siCTR. siB55a, or siPHD2, alone or in combination. After 24 hr, cells were incubated either in
normoxia (NRX, 21% O2) or hypoxia (HPX, 1% O2) for 16 hr, and WCEs were analyzed by WB.
(legend continued on next page)
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B55a knockdown had an additive effect (Figure 3G), supporting
the idea that inhibition of mTOR/P70S6K-mediated PHD2 phos-
phorylation and activation of B55a are simultaneous events,
both required for full accumulation of HIF1a in hypoxia.
Next we investigated the mechanism(s) underlying PP2A
activation. Several reports have shown that mTOR blockade re-
leases PP2A activity (Cianfanelli et al., 2015; Hartley and Cooper,
2002; Peterson et al., 1999), and it is widely accepted that the
mTOR pathway is inhibited by hypoxia (Sofer et al., 2005).
Accordingly, our experiments showed progressive P70S6K
deactivation in hypoxia (Figure 3D). We therefore measured
PP2A/B55a activity in the presence of themTOR blockers Torin2
or Rapamycin. Consistent with our hypothesis, we could
observe a great increase in PP2A activity with both inhibitors
(Figure 3H). Conversely, reactivation of mTOR signaling in hyp-
oxia by REDD1 silencing prevented the activation of PP2A (Fig-
ure S2C). To further ascertain the involvement of P70S6K in this
loop, we analyzed the effect of P70S6K or B55a silencing alone
or in combination. Because activation of P70S6K was nearly
abolished after 24 hr of hypoxic conditions (Figure 3D), experi-
ments were performed at 4 hr of hypoxia; silencing of P70S6K
or B55a oppositely regulated HIF1a levels, as already previously
observed. Interestingly, combined P70S6K and B55a knock-
down caused a further increase in HIF1a, indicating that
silencing of P70S6K prevails over the loss of B55a/PP2A activity
(Figure 3I). In summary, inactivation of the mTOR/P70S6K
pathway by REDD1/hypoxia leads to increased PP2A function,
PHD2 dephosphorylation, and, thus, HIF1a stabilization.
HIF1a Stabilization by PP2A/B55a Promotes Colorectal
Cancer Cell Survival via Autophagy in a PHD2-
Dependent Manner
In hypoxia, HIF1a stabilization promotes cancer cell survival by
initiating autophagy, a process that requires transcriptional in-
duction of BNIP3 andBNIP3L, leading to tumor progression (Ma-
zure and Pouysse´gur, 2009). We thus speculated that PHD2
regulation by B55a might somehow modify cell viability in nor-
moxia and/or in hypoxia. To explore this possibility, DLD1 cells
stably knocked down for PHD2 or B55a, alone or in combination,
were exposed to 21% or 1% oxygen. When exposed to hypoxia,(C) DLD1 cells were stably silenced for control, B55a, PHD2, or both (shCTR,
transiently transfected with a hypoxia-response element (HRE)-Luc reporter and i
activity was measured and normalized for protein concentration.
(D)WB of DLD1 cells transiently transfectedwith siCTR siB55a and incubated in no
of three independent experiments.
(E) DLD1 cells were incubated in normoxia or hypoxia for the indicated time in the p
acid (NEN)/mL.WCEswere collected and immunoprecipitated with anti-PHD2 ant
screen overnight. The graph shows the quantification and mean of two independ
(F)Measurement of the enzymatic activity of PP2A/B55a fromWCEs of DLD1 cells
with siB55a and incubated in hypoxia for 16 hr. OA and silencing of B55a siB55a
(G) WB of DLD1 cells transiently transfected with siCTR, siB55a, or REDD1 (siRE
16 hr.
(H) Measurement of the enzymatic activity of PP2A/B55a from WCE of DLD1 cel
16 hr.
(I) HEK393T cells were transfected with siCTR, siB55a, or siP70, alone or in com
analyzed by WB.
All WBs were repeated three times on independent biological replicates. *p < 0.05
conditions in (F), and versusMock in (H); #p < 0.05 versus all other conditions unde
See also Figure S2.cells depleted for B55a showed a significant increase in cell
death compared with control cells, as assessed by measuring
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining or cleaved Poly(ADP-ribose) polymerase
(PARP). Simultaneous depletion of PHD2 was able to rescue
the increased cell death, indicating that B55a requires PHD2 to
elicit its effect (Figures 4A and 4B; Table S5). The proliferation
rate and cell cycle were both comparable under all conditions
tested, either normoxia or hypoxia (Figures S3A–S3C). We then
wondered whether B55a could promote hypoxic cell survival
via autophagy. Hypoxic exposure of DLD1 control cells for
16 hr induced the autophagy markers BNIP3 and BNIP3L; how-
ever, B55a silencing prevented this upregulation. Concomitant
depletion of PHD2 and B55a restored BNIP3 and BNIP3L levels
back to the control level, supporting the idea of a PHD2-depen-
dent role of B55a in hypoxia-induced autophagy (Figures 4C
and 4D). To assess the influence of B55a in this process, we
measured the autophagic substrates p62 and LC3B, which
are, respectively, degraded and induced during autophagy. Un-
der hypoxia, p62 halved and LC3B doubled in control cells, but
B55a knockdown partially prevented this process in a PHD2-
dependent manner (Figure 4E; Figure S3D; Table S5). To assess
the link between autophagy and survival in hypoxia, DLD1 cells
were silenced for B55a, for the autophagy-mediator Atg5 (Pyo
et al., 2005), or for both (Figures S3E and S3F). In hypoxia,
each silencing alone caused increased cell death and a reduc-
tion in LC3-II levels compared with the control, but combined
knockdown of B55a and Atg5 was not synergic, suggesting
that B55a exerts its mechanism of action on the same pathway
of Atg5 (Figure 4F; Figure S3G).
To assess whether the effect of B55a knockdown on hypoxia-
induced autophagy wasmediated by a reduction in HIF1a levels,
B55a-silenced and control cells were stably transfected with
HIF1aP402A/P564G, a HIF1a double proline mutant insensitive to
PHD-dependent degradation (Figure 4G; Table S5). As above,
exposure to hypoxia promoted cell survival in control cells but
much less in B55a-silenced cells; this phenotype was rescued
upon concomitant overexpression of HIF1aP402A/P564G (Fig-
ure 4H). Consistently, HIF1aP402A/P564G overexpression also
rescued the decrease in LC3-II levels observed upon B55ashB55a, shPHD2, and shPHD2rshB55a, respectively). These cells were then
ncubated for 16 hr in normoxia or hypoxia. Cells were then lysed, and luciferase
rmoxia or in hypoxia for the indicated time. The graph represents quantification
resence of a phosphate-freemedium containing 1mCi of [32P]orthophosphoric
ibody. After blotting, themembranewas exposed to a Kodak phosphor imaging
ent experiments.
incubated in normoxia (CTRL) and hypoxia for the indicated time or transfected
were used as negative controls.
DD1) alone or in combination and incubated either in normoxia or hypoxia for
ls untreated (Mock) or incubated with 200 nM Torin2 and 1 mM Rapamycin for
bination. After 16 hr, cells were exposed to hypoxia for 4 hr, and WCEs were
versus all other conditions under NRX in (C), versus 0 hr + 32P in (E), versus all
r HPX in (C) and versus 0 hr and 4 hr + 32P in (E). The graphs showmean ±SEM.
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Figure 4. Silencing of B55a Induces Increased Apoptosis in Hypoxia in a PHD2-Dependent Manner
(A and B) DLD1 cells stably silenced for control, B55a, PHD2, or both (shCTR, shB55a, shPHD2, and shPHD2rshB55a, respectively) were cultured in normoxia or
hypoxia for 96 hr (A) or 72 hr (B). Apoptosis was assessed by TUNEL staining (ApopTag) (A) or PARP cleavage (B).
(C and D) DLD1 cells stably silenced as in (A) were cultured in normoxia and in hypoxia for 16 hr. BNIP3 (C) and BNIP3L (D) mRNA levels were assessed by
qRT-PCR.
(E) DLD1 cells stably silenced as in (A) were cultured in normoxia or hypoxia for 48 hr, and WCEs were analyzed by WB.
(F) DLD1 cells stably silenced for control, B55a, Atg5, or both (shCTR, shB55a, shAtg5, and shAtg5rshB55a, respectively) were cultured in normoxia or hypoxia
for 96 hr. Apoptosis was assessed by TUNEL staining.
(G–I) DLD1 cells stably silenced for control (shCTR) or B55a (shB55a) were transduced with lentiviral vectors to stably express an empty vector or a hydroxylation-
insensitive HIF1a (HIF1a-PP) (G). The cells were then cultured in normoxia or hypoxia for 96 hr, and apoptosis was assessed by TUNEL staining (H). The same
cells were exposed to hypoxia for 48 hr, and WCEs were analyzed by WB (I).
All WBs were repeated three times on independent biological replicates. *p < 0.05 versus all other conditions in (A), (C), (D), and (H) and versus shCTR in (F). The
graphs show mean ± SEM. See also Figure S3.
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Figure 5. PP2A/B55a Promotes Colorectal Cancer Growth in a PHD2-Dependent Manner
(A–I) Focus formation assaywith DLD1 cells stably silenced for control, B55a, PHD2, or both (shCTR, shB55a, shPHD2, and shPHD2rshB55a, respectively) (A–C),
with DLD1 shCTR and shB55a stably transducedwith an empty vector or a hydroxylation-insensitive HIF1a (EV, shB55a, HIF1a, and shB55arHIF1a) (D–F), or with
DLD1 cells stably silenced for control, B55a, Atg5 or both (shCTR, shB55a, and shAtg5, shAtg5rshB55a, respectively) (G–I). Representative images from one of
three independent experiments are shown (A, D, and G). The graphs show the size (B, E, and H) and total number (C, F, and I) of colonies per well.
(legend continued on next page)
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depletion (Figure 4I; Table S5). Thus, the pro-apoptotic effect
seen after B55a silencing is dependent on a decrease in HIF1a
levels because of sustained PHD2 activity under hypoxia.
PP2A/B55a Promotes Colorectal Cancer Growth in a
PHD2-Dependent Manner
To elucidate the meaning of the B55a-PHD2 axis on tumorigen-
esis, we performed a focus-forming assay and a soft agar assay
reflecting, respectively, the ability of cancer cells to bypass con-
tact inhibition and to grow in the absence of adhesion. In both as-
says, uncontrolled growth led to increased oxygen consumption
(Figure S4A; Leontieva et al., 2014). B55a silencing resulted in
a significant reduction in colony size and number compared
with the scrambled control and to PHD2 silencing (Figures 5A–
5C; Figures S4B–S4D). This effect was rescued when B55a
and PHD2 were concomitantly knocked down (Figures 5A–
5C; Figures S4B–S4D), confirming that B55a works as a nega-
tive modulator of PHD2. Overexpression of undegradable
HIF1aP402A/P564G abrogated the decrease in colony size and
density caused by B55a knockdown but did not affect the
growth of control cells (Figures 5D–5F). To link the reduction in
focus formation to impairment of the autophagic pathway, we
measured colony size and numbers following single or combined
knockdown of B55a and Atg5. Each silencing was equally effec-
tive in inhibiting colony formation, but the combined knockdown
of B55a and Atg5 was not synergic, suggesting that autophagy-
induced cancer cell survival by B55a unleashes its tumorigenic
potential (Figures 5G–5I).
In vivo, silencing of B55a in DLD1 or HT29 cells subcutane-
ously injected into nude mice resulted in the formation of smaller
tumors. This effect was PHD2-dependent because concomitant
silencing of PHD2 prevented it, whereas PHD2 knockdown alone
did not affect cancer growth (Figures 5J–5M). In line with our
in vitro experiments, compared with the control, cell death and
autophagy in the hypoxic (pimonidazole-positive) niches of the
tumor were, respectively, increased and reduced upon B55a
silencing but rescued by combined knockdown of B55a and
PHD2; PHD2 silencing alone did not affect either parameters
(Figures 5N and 5O). Conversely, cancer cell proliferation
was not significantly affected (Figure S4E). In addition, stromal
component such as leukocyte infiltration and blood vessel den-
sity were similar under all experimental conditions (Figures S4F
and S4G). Overall, these findings indicate that PP2A/B55a plays
a pro-tumoral role by inactivating PHD2.
By using CRIPSR/Cas9, we generated PHD2 KO HT29 cells
(Figure S4H) that were then reconstituted with either PHD2WT,(J and K) In vivo growth curves of xenograft tumors derived by subcutaneous injec
PHD2, or both (shCTR, shB55a, shPHD2, and shPHD2rshB55a, respectively).
(L and M) Tumor weights of HT29 (L) or DLD1 (M) cells 24 or 23 days after tumor
(N) Morphometric quantification of DLD1 tumor sections stained for ApopTag sh
(O) Morphometric quantification of DLD1 tumor sections stained for LC3 and PIM
three independent experiments using seven or eight mice per condition in each
(P) WB analysis for HIF1a and PHD2 from control HT29 (guide RNA [gRNA]CTRL)
constituted with a lentiviral vector encoding PHD2WT, PHD2S125A, and PHD2S125
(Q) In vivo growth curve of xenograft tumors derived by subcutaneous injection
PHD2WT, PHD2S125A, and PHD2S125D. The data combine two independent experi
twice.
*p < 0.05 versus all other conditions; #p < 0.05 versus PHD2S125A. The graphs sh
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levels of HIF1a according to our previous in vitro data, with
PHD2S125A and PHD2S125D being, respectively, less and more
active than the wild-type isoform (Figure 5P). In vivo, HT29 cells
expressing PHD2S125D showed a significant reduction in tumor
growth comparedwith cells expressing PHD2S125A; PHD2WT-ex-
pressing cells displayed, instead, an intermediate phenotype
(Figure 5Q). In sum, PHD2S125D mutant mimics B55a silencing,
both of which have an antitumor effect.
Finally, we collected tumor tissues and normal counterparts
from CRC patients, and B55a, HIF1a, and REDD1 protein levels
were analyzed by western blot. Compared with normal colon, all
tumor samples displayed increased protein levels of HIF1a,
B55a, and REDD1 (Figures 6A–6D). Importantly, targeted mass
spectrometry revealed that the fraction of phospho-S125 in
cancerous colon tissue was about 60% decreased compared
with healthy colon (Figure 6E; Figures S5A and S5B). Consistent
with the induction of PHD2 by HIF1 itself (Fong and Takeda,
2008), the total amount of PHD2 was slightly higher in the tumor
compared with normal tissue, although this difference did not
reach significance (Figure 6F). Overall, these observations high-
light the relevance of B55a-PP2A signaling in the regulation of
PHD2 phosphorylation and HIF1a accumulation in CRC.
According to our model, it follows that, subsequent to an
mTOR block in hypoxia, not only the phosphorylation of PHD2
by P70S6K is inhibited but PP2A/B55a activity is also liberated
(Hartley and Cooper, 2002; Peterson et al., 1999; Roberts
et al., 2014). Interestingly, B55a silencing prevents P70S6K
inactivation, indicating that the phosphorylation and dephos-
phorylation machineries of PHD2 are mutually exclusive. As a
consequence, increased dephosphorylation on S125 results in
impaired enzymatic activity of PHD2. Consequently, HIF1a ac-
cumulates and favors cancer cell survival and tumor growth
(Figure 6G).
DISCUSSION
PHD2 is the main regulator of HIF1a, one of the key responders
to hypoxia, and broadly expressed in tumors (Keith et al., 2011).
Although it is generally accepted that oxygen is the most impor-
tant determinant of PHD2 activity, here we investigate the
possible involvement of oxygen-independent, post-translational
modification of PHD2. We find that the phosphorylation status of
PHD2 is important for efficient control of HIF1 levels. The kinase
P70S6K and the phosphatase PP2A/B55a directly phosphory-
late and dephosphorylate PHD2 on S125.When S125 ismutatedtion in nudemice of HT29 (J) or DLD1 (K) cells stably silenced for control, B55a,
cell injection, respectively.
owing apoptosis in the PIMO-positive area of the tumor.
O, showing autophagy in hypoxic areas of the tumor. The data combine two or
experiment.
and HT29 cells knocked out for PHD2 by means of a gRNAPHD2 and then re-
D or an EV.
into nude mice of PHD2 knockout HT29 cells (gRNAPHD2) stably expressing
ments using six mice per condition in each experiment. The WB was repeated
ow mean ± SEM. See also Figure S4.
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Figure 6. Evidence of the B55a-PHD2-HIF1a Axis in Colorectal Cancer Patients
(A–D) WB analysis (A) and quantification of B55a (B), HIF1a (C) and REDD1 (D) protein levels in normal or tumor colorectal cancer tissues from ten colorectal
cancer patients. Vinculin was used as a loading control.
(E and F) LC/MS-based quantification of phosphorylated S125 over total PHD2 ratios in healthy versus colorectal cancer tissues using targeted PRM and SIL
reference peptides. The fraction of S125 phosphorylation on total PHD2 in healthy tissue is normalized to 1 (E). Total PHD2 levels are shown in (F). **p < 0.01
versus the other condition. The graphs show mean ± SEM. See also Figure S5.
(G) Schematic of the pathways controlling the phosphorylation status of PHD2 on S125 and the levels of HIF1a. The mTOR downstream kinase P70S6K is
responsible for the direct phosphorylation of PHD2. Instead, PP2A/B55a is responsible for the direct dephosphorylation, leading to a partial inactivation of PHD2
even when oxygen is not limiting. In hypoxia, the mTOR pathway is inhibited, and, as a consequence, PP2A/B55a activity is liberated. It follows that P70S6K is
blocked by both PP2A and by the inhibition of mTOR. The enzymatic release of PP2A/B55a and the inhibition of P70S6K lead to complete dephosphorylation of
PHD2 on S125, resulting in the overall reduction of its activity and accumulation of HIF1a. After stabilization, HIF1a promotes hypoxic cell survival via autophagy
and fosters tumor growth.to alanine, PHD2 shows an impaired ability to degrade HIF1a or
an ODDD luciferase fusion protein, which is associated with a
reduction of OH-HIF1a, indicating a crucial role of S125 phos-
phorylation in modulating PHD2 activity.
The mechanism by which this phosphorylation modifies PHD2
activity remains to be elucidated. Indeed, S125 is a residuelocated at the N terminus of the protein and does not involve
its catalytic domain. Moreover, although others have shown
that phosphorylation on PHD1 S130 by CDK1 affects the binding
affinity of PHD1 for HIF1a (Ortmann et al., 2016), the phosphor-
ylation status of PHD2 on S125 does not affect the interaction
between PHD2 and HIF1a (data not shown). Therefore, thisCell Reports 18, 1699–1712, February 14, 2017 1709
phosphorylation site might be relevant for the affinity of PHD2 for
oxygen and/or cosubstrates or for other partners, such as LIMD1
or von Hippel-Lindau (VHL) (Foxler et al., 2012).
In hypoxia,mTOR inhibition prohibits P70S6Kactivity, which, in
turn, unleashes PP2A/B55a signaling. The downregulation of
P70S6K, a kinase targeting PHD2, and the mutual upregulation
of PP2A/B55a phosphatase activity lead to dephosphorylation
and partial inactivation of PHD2, ultimately promoting HIF1a sta-
bilization (Figure 6G). These data therefore indicate a hypoxic
regulatory flow that starts with downregulation of P70S6K activity
and moves to the activation of PP2A/B55a. The combined action
of these processes potentiates/accelerates the inactivation of
PHD2duringhypoxia, leading toHIF1a stabilization. Furthermore,
HIF1a, by promoting REDD1 transcription (Brugarolas et al.,
2004), contributes tomTOR inactivation, thus enforcing a positive
feedback loop that promotes survival of hypoxic tumor cells.
With these data, we add a further piece to the crosstalk be-
tween mTOR and HIF1a. It has been reported that the mTOR
pathway controls HIF1a protein synthesis in normoxia (Brugaro-
las et al., 2004; Hudson et al., 2002). Here we explain how HIF1a
can be stabilized under low oxygen availability or nutrient starva-
tion (Nishimoto et al., 2014), two conditions that turn off the
mTOR pathway. Accordingly, REDD1 blockade and subsequent
mTOR activation have been linked to an antitumoral response,
and REDD1 overexpression has been described in CRC as
well as in several other tumor types (Chang et al., 2009; Jia
et al., 2014; Kucejova et al., 2011) (http://www.cbioportal.org/).
It is reasonable that these tumors are highly hypoxic, and
REDD1 overexpression upregulates hypoxia-induced genes
(Brugarolas et al., 2004). In the opposite scenario, in normoxic
cells, active mTOR/P70S6K increases HIF1a translation, but
PHD2 activity is promoted as well so that, ultimately, excessive
HIF activation is prevented.
According to our model, HIF1a stabilization by PP2A will
initiate an adaptive response, allowing cells to survive the hostile
conditions that characterize the tumor microenvironment (Keith
et al., 2011). Although autophagy in cancer has been associated
with opposing functions (Mathew et al., 2007; Shchors et al.,
2015), autophagy in CRC cells has been shown to be pro-sur-
vival following amino acid starvation (Sato et al., 2007). Here
we demonstrate that hypoxia is able to trigger autophagic sur-
vival through stabilization of HIF1a levels, which requires PHD2
dephosphorylation by PP2A/B55a. In this way, the protective
role of HIF1a is cell-autonomous and not due to the indirect ef-
fect of this pathway on the tumor stroma, such as via vascular
endothelial growth factor (VEGF) production and blood vessel
formation (Tsuzuki et al., 2000). However, prolonged activation
of the autophagic process would lead to excessive self-eating
with consequent induction of cell death (Liu and Levine, 2015).
Transcriptional induction of PHD2 upon chronic hypoxia (Epstein
et al., 2001) will overrule the inhibition of PHD2 by PP2A, bringing
HIF1a to lower levels and turning off autophagy. In this scenario,
a post-translational modification represents the fastest way for
the cell to survive.
It has already been shown that B55a is induced in cancer cells
at both the transcript and protein levels when the key metabolite
glutamine becomes limited or upon DNA damage (Kalev et al.,
2012). The ability of B55a silencing to abate the neoplastic fea-1710 Cell Reports 18, 1699–1712, February 14, 2017tures of HT29 and DLD1 cells in vitro and in vivo indicates that
B55a can have a pro-survival, tumor-promoting role in colorectal
cancer, supported by our study in a small cohort of CRC patients
andby recentdata showing that, of all theBsubunits, onlyB55a is
specifically upregulated in CRC human samples (Gilan et al.,
2015). Another study has reported a significant association be-
tween expression of HIF1a and CRC staging, involvement of
lymph nodes, and liver metastases, resulting in an inverse corre-
lation betweenHIF1a levels and overall survival (Cao et al., 2009).
Because we have shown that HIF1a levels positively correlate
with B55a because of its negative modulation of PHD2, we sug-
gest that targeting B55amight serve as a promising therapeutic
approach for CRC, especially to tackle tumors overexpressing
HIF1a. So far, the pan-PP2A inhibitor okadaic acid has been
shown to promote tumor growth and is associated with adverse
reactions (Bialojan and Takai, 1988). This is due to the pleiotropic
andmultifunctional role of 100 combinations of the PP2A holoen-
zyme. Based on our observation, we speculate that a molecule
capable of blocking B55a or, even more specifically, the interac-
tion between B55a and PHD2, might display higher selectivity
with an univocal anti-tumor effect and, likely, lower toxicity.
At this stage, our study provides insights into how, in the
context of CRC, a specific post-translational modification of
PHD2 can promptly activate a survival response by controlling
HIF1a in an oxygen-independent manner, thus extending the
role of PHD2 beyond its initially recognized function as an oxy-
gen sensor.
EXPERIMENTAL PROCEDURES
More detailed methods can be found in the Supplemental Experimental
Procedures.
Cell Culture and Transfections
HEK293T, DLD1, and HT29 cell lines were routinely cultured in DMEM (Gibco)
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco),
2 mM glutamine (Life Technologies), and 100 units/mL penicillin and
100 mg/mL streptomycin (Life Technologies). Cells were maintained in a
humidified incubator at 37C and 5% CO2. For hypoxia experiments, cells
were incubated in a hypoxic glovebox (37C, 5%CO2, 1%O2) for the indicated
times. Transfections were performed with Lipofectamine 2000 transfection
reagent or Lipofectamine RNAiMax (Life Technologies) according to the
manufacturer’s instructions.
Phosphatase Assay
Phosphatase assays were performed by using DuoSet IC-human/mouse/rat
active PP2A (R&D Systems) according to the manufacturer’s instructions.
100 mg of whole-cell extract from DLD1 cells was added to PP2A antibody-
coated wells. Recombinant PHD2 peptide (amino acids [aa] 113–130) synthe-
tized by Pepscan and the positive control (serine/threonine phosphatase
substrate I, part 842098) were used as phosphatase substrates.
Kinase Assay
The purified wild-type or mutant PHD2-FLAGM2 proteins (100 ng) were incu-
bated in kinase buffer (25 mM 3-Morpholinopropane-1-sulfonic acid (MOPS)
[pH 7.2], 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 250 mM DTT, and 6 mM
b-glycerophosphate) in the presence of active P70S6K (4 ng/mL, SignalChem),
250 mM ATP, and 2 mCi g-32P-ATP (PerkinElmer). After 20-min incubation at
30C, samples were denaturated by incubating with 43 SDS sample buffer
at 95C for 10 min and separated by 10% SDS-PAGE. Thereafter, the gel
was blotted onto a nitrocellulose membrane, and the membrane was exposed
to a Kodak phosphor imaging screen overnight. Autoradiography was
detected with MolecularImager FX using Quantity One software (all from Bio-
Rad). Afterward, the total proteins were detected by using an antibody against
PHD2.
Focus Formation and Soft Agar Assay
For the focus formation assay, DLD1 cells were plated at 23 103 cells/well on a
6-well cell culture plate and cultured for 10 days. The cultured cells were
stained and fixed with 0.5% crystal violet in a fixating solution containing
10% acetic acid and 10% methanol in water. For the soft agar assay, 103
DLD1 cells were suspended in 2 mL of 0.5% (w/v) agar containing DMEM/
10% fetal bovine serum on a 1% (w/v) agar solution in 24-well plates. Colonies
appeared microscopically after 10 days and were visible to the naked eye after
15–20 days of incubation.
Xenograft Tumors
DLD1 and HT29 cells were harvested, and single-cell suspensions of 3 – 106
cells in 200 mL of PBS were injected subcutaneously into the right flanks of
nude mice. Tumor volumes were measured three times a week with a caliper
and calculated using the following formula: V = p3 [d23 D] / 6, where d is the
minor tumor axis and D is the major tumor axis. All the experimental proced-
ures were approved by the Institutional Animal Care and Research Advisory
Committee of the KU Leuven.
CRC Patient Selection
For this study, ten patients diagnosed with CRC who underwent surgical
resection were selected. This study was approved by the institutional ethical
commission at the University Hospital of Leuven, Belgium.
Statistics
All statistical analyseswere performed usingGraphPad Prism software. Statis-
tical significance was calculated by two-tailed unpaired t test on two experi-
mental conditions or two-way ANOVA when more than two groups were
compared, with p < 0.05 considered statistically significant. Western blots
and immunoprecipitations are representative of three independent experi-
ments. Focus formation assays, qRT-PCR, luciferase assays, and phospha-
tase assays are representative of three independent biological experiments
where each experiment was done by three technical replicates. All graphs
show mean values ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2017.01.051.
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